Zilarbi CN 10 Tablet (Azilsartan medoxomil 40mg / Cilnidipine 10mg)
$48.00 – $121.00
| Country of Origin | india |
|---|---|
| Dosage Form | Tablets |
| Generic Name | Azilsartan medoxomil |
| Indication | Treatment of Hypertension (high blood pressure) |
| Packaging | 15 tablets in a strip |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Composition | Azilsartan medoxomil (40mg) + Cilnidipine (10mg) |
| Zilarbi CN 10 Tablet (Azilsartan medoxomil 40mg / Cilnidipine 10mg) | |||
| Pack Size | Price | Price/Unit | Add To Cart |
| 60 Tablet/s | $48.00 (0.8/unit) | $0.8 | |
| 120 Tablet/s | $88.00 (0.73/unit) | $0.73 | |
| 180 Tablet/s | $121.00 (0.67/unit) | $0.67 | |
Usage:
Hypertension (high blood pressure),Heart failure,Hypertension (high blood pressure),
How to Use:
Most side effects do not require any medical attention and disappear as your body adjusts to
the medicine. Consult your doctor if they persist or if you’re worried about them
Side Effects:
Dizziness,Muscle damage,Diarrhea,Fatigue,Ankle swelling,Sleepiness,Flushing (sense of warmth in the face, ears, neck and trunk),Headache,Nausea,Dizziness,Palpitations,Edema (swelling),Abdominal pain,
Safety Information:
- Keep this medicine out of reach of children.
- Store away from direct sunlight .
- Do not use this medicine after the expiry date.
- Do not exceed the recommended dosage.
Be the first to review “Zilarbi CN 10 Tablet (Azilsartan medoxomil 40mg / Cilnidipine 10mg)”
Related products
Angina Pectoris Anti-Anginals
$25.00 – $82.00
Heart & Blood Pressure
$36.00 – $90.00
Angina Pectoris Anti-Anginals
$42.00 – $102.00
Angina Pectoris Anti-Anginals
$25.00 – $82.00
Angina Pectoris Anti-Anginals
$39.00 – $95.00
Angina Pectoris Anti-Anginals
$39.00 – $95.00
Angina Pectoris Anti-Anginals
$23.00 – $40.00
Angina Pectoris Anti-Anginals
$49.00 – $131.00
Angina Pectoris Anti-Anginals
$42.00 – $112.00
Angina Pectoris Anti-Anginals
$55.00 – $170.00
Angina Pectoris Anti-Anginals
$45.00 – $150.00
Angina Pectoris Anti-Anginals
$39.00 – $95.00
Reviews
There are no reviews yet.